AVEO Oncology Announces Updated Overall Survival Hazard Ratio Of 0.99 In Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 10, 2019-- AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3 is the Company’s Phase...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma